NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Conditions
- Non-small Cell Lung Cancer
Interventions
- DRUG: NAP (Naptumomab estafenatox)
- DRUG: Docetaxel
- DRUG: Obinutuzumab
Sponsor
NeoTX Therapeutics Ltd.
Collaborators